Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial

CURRENT-OASIS 7 trial investigators, Shamir R Mehta, Jean-Francois Tanguay, John W Eikelboom, Sanjit S Jolly, Campbell D Joyner, Christopher B Granger, David P Faxon, Hans-Jurgen Rupprecht, Andrzej Budaj, Alvaro Avezum, Petr Widimsky, Philippe Gabriel Steg, Jean-Pierre Bassand, Gilles Montalescot, Carlos Macaya, Giuseppe Di Pasquale, Kari Niemela, Andrew E Ajani, Harvey D WhiteSusan Chrolavicius, Peggy Gao, Keith A A Fox, Salim Yusuf

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

Clopidogrel and aspirin are the most commonly used antiplatelet therapies for percutaneous coronary intervention (PCI). We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI.
Original languageEnglish
Pages (from-to)1233-43
Number of pages11
JournalThe Lancet
Volume376
Issue number9748
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial'. Together they form a unique fingerprint.

Cite this